Number needed to treat to harm for discontinuation due to adverse events in the treatment of bipolar depression, major depressive disorder, and generalized anxiety disorder with atypical antipsychotics.
Gao
Keming
K
Department of Psychiatry, Mood and Anxiety Clinic in the Mood Disorders Program, University Hospitals Case Medical Center, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA. keming.gao@uhhospitals.org
Kemp
David E
DE
Fein
Elizabeth
E
Wang
Zuowei
Z
Fang
Yiru
Y
Ganocy
Stephen J
SJ
Calabrese
Joseph R
JR
D016907:Adverse Drug Reaction Reporting Systems; D017109:Akathisia, Drug-Induced / Q000209:etiology; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D001008:Anxiety Disorders / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D001480:Basal Ganglia Diseases / Q000139:chemically induced; D001714:Bipolar Disorder / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D003692:Delayed-Action Preparations; D003865:Major Depressive Disorder / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D006970:Disorders of Excessive Somnolence / Q000139:chemically induced; D004305:Dose-Response Relationship, Drug; D057915:Drug Substitution; D006801:Humans; D011358:Product Surveillance, Postmarketing; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D014851:Wakefulness / Q000187:drug effects; D015430:Weight Gain / Q000187:drug effects
D014150:Antipsychotic Agents; D003692:Delayed-Action Preparations